Strategic Collaboration Selah Genomics partners with healthcare providers and pharmaceutical industry for advanced molecular and genomic diagnostics, creating cross-selling opportunities with hospitals, clinics, and pharma companies focused on oncology and infectious disease.

Targeted Diagnostics Current focus on oncology and infectious disease diagnostic tests suggests sales opportunities should emphasize expanding to cardiovascular and genetic risk testing, leveraging the recent cardiovascular genetic test launch to broaden addressing clinicians' needs.

Growing Revenue With revenue in the low millions and a lean team, there is potential to scale through strategic partnerships, channel integrations, and contract-based services with larger diagnostics players or contract research organizations seeking genomic capabilities.

Clinical Trial Enablement Position Selah as a partner for early-stage drug development and regulatory processes, offering genomic and molecular diagnostics that support patient stratification, biomarker discovery, and trial readiness for pharma clients.

Market Differentiation Highlight rapid expansion of advanced tests and personalized medicine focus as a competitive edge against larger labs, while exploring co-development or white-label opportunities with established players to accelerate market access.